However, when combined with baicalein, metformin significantly reduced cancer cell viability at a much lower IC50 and more effectively inhibited the AMPK/PI3K/mTOR pathway, indicating that baicalein sensitizes cancer cells to metformin’s effects. The gene discussed is MTOR; the disease is cancer.